Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gentian Diagnostics ASA ( (DE:6FK) ) has issued an announcement.
Gentian Diagnostics ASA reported record sales of NOK 42.6 million in Q4 2024, marking a 14% increase compared to Q4 2023, and a full-year revenue increase of 13%. The company saw significant growth in their fCAL® turbo sales, especially in the US, where sales grew by 101% in Q4 2024. The company’s profitability improved with a gross margin increase to 56% and a positive EBITDA of NOK 8.1 million for Q4 2024. The board proposed a NOK 0.40 per share dividend, reflecting a strong cash position and sound earnings. The company’s NT-proBNP assay development is on track, and collaborations with clinical partners have been enhanced to secure more clinical cohorts.
More about Gentian Diagnostics ASA
Gentian Diagnostics ASA is a rapidly expanding company that develops and manufactures high-quality in vitro diagnostic reagents. The company specializes in immunoassays for infections, inflammation, kidney failure, and congestive heart failure. By converting existing biomarkers to automated, high-throughput analyzers, Gentian aims to reduce costs and improve healthcare outcomes. Headquartered in Moss, Norway, the company serves global human and veterinary diagnostics markets with operations in Sweden, USA, and China.
YTD Price Performance: 22.50%
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: €63.79M
For a thorough assessment of 6FK stock, go to TipRanks’ Stock Analysis page.